{"organizations": [], "uuid": "f4a74b5350b5981478f9eef98bd046625570a69e", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/03/27/globe-newswire-beyondspring-to-host-fourth-quarter-and-full-year-2017-financial-results-conference-call-on-april-3-2018.html", "country": "US", "domain_rank": 767, "title": "BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.022, "site_type": "news", "published": "2018-03-28T00:05:00.000+03:00", "replies_count": 0, "uuid": "f4a74b5350b5981478f9eef98bd046625570a69e"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/03/27/globe-newswire-beyondspring-to-host-fourth-quarter-and-full-year-2017-financial-results-conference-call-on-april-3-2018.html", "ord_in_thread": 0, "title": "BeyondSpring to Host Fourth-Quarter and Full-Year 2017 Financial Results Conference Call on April 3, 2018", "locations": [], "entities": {"persons": [], "locations": [{"name": "new york", "sentiment": "none"}, {"name": "u.s.", "sentiment": "none"}], "organizations": [{"name": "beyondspring inc.", "sentiment": "negative"}, {"name": "company", "sentiment": "none"}, {"name": "university of washington", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (NASDAQ:BYSI), a global, clinical-stage biopharmaceutical company focused on the development of transformative cancer therapies, today announced that the Company will report fourth-quarter and full-year 2017 financial results on Tuesday, April 3, 2018. BeyondSpring’s management team will host a conference call and webcast at 8:00 a.m. Eastern Time on Tuesday, April 3, 2018, to discuss the financial results and provide an operational update.\nThe conference call may be accessed by dialing (866) 362-6591 (U.S.) or (706) 758-3199 (international) and referencing conference ID 3765248. A live webcast will be available on the Investors page of the Company's website at http://ir.beyondspringpharma.com . An archived replay of the webcast will be available for 30 days.\nAbout BeyondSpring\nBeyondSpring is a global, clinical-stage biopharmaceutical company developing innovative immuno-oncology cancer therapies with a robust pipeline from internal development and from collaboration with University of Washington in de novo drug discovery using ubiquitination platform. BeyondSpring’s lead asset, Plinabulin, is in a Phase 3 clinical trial as a direct anticancer agent in non-small cell lung cancer (Study 103) and two Phase 2/3 clinical programs in the prevention of chemotherapy-induced neutropenia (CIN) – (Studies 105 and 106). BeyondSpring has a seasoned management team with many years of experience bringing drugs to market.\nContact:\nInvestor Relations:\nLaura Perry or Joe Rayne\nArgot Partners\n212.600.1902\nBeyondSpring@argotpartners.com\nSource:BeyondSpring, Inc.", "external_links": ["https://www.globenewswire.com/Tracker?data=nxsFT_rQxgLOzTi3Jh8B7UfDkxRrXolQggVn5R7-cR8Mvlxt4sA3ZpAc2_b9KOttn_ReIRu9QuU9TtHFGZHfQgQMxDpt6JFo4YYCbRX71QtVlio1ZjC12BMdseYTjtKk", "https://www.globenewswire.com/Tracker?data=sBG40GL4D0tiJ7SWUoENgnwV97GgYX5ttotLXGJqDA6H8ODcUYYVtTYNgpxULYu56zPhsre8AKrPHrznNc-o51vFAcKHDh8cjNwQstNNlRzuLggLzmGfqGU9tpfv9kIX"], "published": "2018-03-28T00:05:00.000+03:00", "crawled": "2018-03-28T04:58:05.032+03:00", "highlightTitle": ""}